Comment on “A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer”, by C. M. Rudin et al. (Ann Oncol 2002; 13: 539–545)

Gautschi, Oliver; Zangemeister-Wittke, U.; Stahel, R. A. (2003). Comment on “A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer”, by C. M. Rudin et al. (Ann Oncol 2002; 13: 539–545). Annals of oncology, 14(1), p. 170. Oxford University Press 10.1093/annonc/mdg001

[img]
Preview
Text
mdg001.pdf - Published Version
Available under License Publisher holds Copyright.

Download (31kB) | Preview

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Gautschi, Oliver

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0923-7534

Publisher:

Oxford University Press

Language:

English

Submitter:

Markus Müller

Date Deposited:

27 Sep 2018 12:26

Last Modified:

24 Oct 2019 02:44

Publisher DOI:

10.1093/annonc/mdg001

BORIS DOI:

10.7892/boris.116047

URI:

https://boris.unibe.ch/id/eprint/116047

Actions (login required)

Edit item Edit item
Provide Feedback